Nisa Leung

Nisa Leung is a Managing Partner of Qiming Venture Partners and leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 5.9 billion in assets and investment in over 380 companies. Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital. She currently sits on the board of Gan & Lee (SSE:603087), Zai Lab (NASDAQ:ZLAB; HKSE:9688), Venus MedTech (HKSE:2500), dMed, CanSino Biologics (SSE:688185; HKSE:6185), Chain Medical Labs, New Horizon Health (SEHK:6606), Berry Oncology, Broncus, Valgen, Insilico Medicine among others. Her other investments include Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, VR Medical, Wuxi Leiming, MEDx, Cure Genetics, SinoCell Tech (SSE:688520), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR) and Jacobio (SEHK:1167) among others. Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019 and 2020, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and Hong Kong Palace Museum.